Novartis | NOVN - Ebitda





Ebitda Veränderung Datum
AbbVie USD 3.69B 1.68B 2026-03
Alcon AG USD 795M 478M 2026-03
Almirall EUR 114.07M 60.37M 2025-12
Amgen USD 3.86B 1.28B 2026-03
AstraZeneca USD 5.16B 510M 2026-06
Autolus Therapeutics Ltd USD -56.8M 13.28M 2026-03
Bayer EUR 2.14B 2.31B 2026-06
Biogen USD 649.7M 76.5M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Eli Lilly USD 10.29B 1.86B 2026-03
Fresenius EUR 988M 37M 2026-06
Fresenius Medical Care EUR 843.66M 19.66M 2026-06
Genmab DKK 401M 186M 2026-06
Gilead Sciences USD 3.51B 489M 2026-03
GlaxoSmithKline GBP 3.51B 734M 2026-06
GRIFOLS EUR 473M 120M 2026-06
Hikma Pharmaceutical USD 369M 84M 2024-12
J&J USD 8.27B 1.08B 2026-03
Lakefront Biotherapeutics EUR -63.7M 624.2M 2026-03
Lonza CHF 1.01B 54M 2025-12
Merck EUR 1.6B 69M 2026-06
Merck USD -1.54B 7.84B 2026-03
Novartis USD 6.48B 1.19B 2026-06
Novartis USD 5.41B 431M 2026-03
Novo Nordisk DKK 37.36B 2.64B 2026-06
Orion EUR 191.9M 61.5M 2026-06
Pfizer USD 6.01B 18M 2026-06
Philips EUR 910M 343M 2026-06
Recordati EUR 256.6M 26.98M 2026-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Roche Holding CHF 13.43B 744M 2026-06
Sanofi EUR 3.69B 375M 2026-06
UCB EUR 1.6B 570M 2025-12